ArticleFrontiers in pharmacology2026

Pharmacologic targeting of midasin (MDN1) reveals a potential therapeutic vulnerability in ESR1-mutant breast cancer.

Mounika Pamukuntla et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.